#1

10/533,683

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1621con

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	OCT 02	CA/CAplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS 3	OCT 19	BEILSTEIN updated with new compounds
NEWS 4	NOV 15	Derwent Indian patent publication number format enhanced
NEWS 5	NOV 19	WPIX enhanced with XML display format
NEWS 6	NOV 30	ICSD reloaded with enhancements
NEWS 7	DEC 04	LINPADOCDB now available on STN
NEWS 8	DEC 14	BEILSTEIN pricing structure to change
NEWS 9	DEC 17	USPATOLD added to additional database clusters
NEWS 10	DEC 17	IMSDRUGCONF removed from database clusters and STN
NEWS 11	DEC 17	DGENE now includes more than 10 million sequences
NEWS 12	DEC 17	TOXCENTER enhanced with 2008 MeSH vocabulary in MEDLINE segment
NEWS 13	DEC 17	MEDLINE and LMEDLINE updated with 2008 MeSH vocabulary
NEWS 14	DEC 17	CA/CAplus enhanced with new custom IPC display formats
NEWS 15	DEC 17	STN Viewer enhanced with full-text patent content from USPATOLD
NEWS 16	JAN 02	STN pricing information for 2008 now available
NEWS 17	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS 18	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS 19	JAN 28	MARPAT searching enhanced
NEWS 20	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS 21	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS 22	JAN 28	MEDLINE and LMEDLINE reloaded with enhancements
NEWS 23	FEB 08	STN Express, Version 8.3, now available
NEWS 24	FEB 20	PCI now available as a replacement to DPCI
NEWS 25	FEB 25	IFIREF reloaded with enhancements
NEWS 26	FEB 25	IMSPRODUCT reloaded with enhancements

NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:34:22 ON 25 FEB 2008

=> FILE REG

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 12:34:44 ON 25 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 24 FEB 2008 HIGHEST RN 1005323-41-0
DICTIONARY FILE UPDATES: 24 FEB 2008 HIGHEST RN 1005323-41-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\LC-52.str





chain nodes :
13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33
34 35 36
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12
chain bonds :
1-19 2-31 3-17 4-29 5-30 6-13 7-35 8-34 9-33 10-32 11-19 12-36 13-14
14-15 14-16 17-18 19-20 20-21 21-22 22-23 22-26 23-24 23-25 26-27 26-28
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12
exact/norm bonds :
6-13 13-14 14-15 14-16 17-18 22-23 22-26
exact bonds :
1-19 2-31 3-17 4-29 5-30 7-35 8-34 9-33 10-32 11-19 12-36 19-20 20-21
21-22 23-24 23-25 26-27 26-28
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12

G1:Cb,Cy,Ak

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS
19:CLASS 20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS
27:CLASS 28:CLASS 29:CLASS 30:CLASS 31:CLASS 32:CLASS 33:CLASS 34:CLASS
35:CLASS 36:CLASS

```
L1      STRUCTURE UPLOADED

=> D L1
L1 HAS NO ANSWERS
L1              STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.


=> S L1 FULL
FULL SEARCH INITIATED 12:35:32 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -       84 TO ITERATE

100.0% PROCESSED       84 ITERATIONS                              19 ANSWERS
SEARCH TIME: 00.00.01

L2           19 SEA SSS FUL L1

=> FILE CAPLUS
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   178.82     179.03

FILE 'CAPLUS' ENTERED AT 12:35:42 ON 25 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 25 Feb 2008  VOL 148 ISS 9
FILE LAST UPDATED: 24 Feb 2008  (20080224/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> S L2
L3           31 L2

=> S L2 AND DEVICE
             31 L2
         901259 DEVICE
L4            1 L2 AND DEVICE

=> S L3 AND DEVICE
         901259 DEVICE
L5            1 L3 AND DEVICE

=> S L3 AND TRANSDERMAL
```

```
        15118 TRANSDERMAL
L6          3 L3 AND TRANSDERMAL

=> S L3 AND DELIVERY
       289142 DELIVERY
L7         14 L3 AND DELIVERY

=> D L7 IBIB ABS HITSTR 1-14
```

L7 ANSWER 1 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2008:70709 CAPLUS
DOCUMENT NUMBER: 148:152045
TITLE: Pharmaceutical preparation for oral administration with controlled active ingredient release in the small intestine and methods for its production
INVENTOR(S): Jung, Gerd; Schaupp, Albert
PATENT ASSIGNEE(S): Dr. R. Pfleger Chemische Fabrik GmbH, Germany
SOURCE: PCT Int. Appl., 41pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008006506	A1	20080117	WO 2007-EP5970	20070705
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
EP 1880718	A1	20080123	EP 2006-14244	20060710
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				

PRIORITY APPLN. INFO.: EP 2006-14244 A 20060710

AB A pharmaceutical preparation for oral administration with controlled active ingredient release in the small intestine, on the basis of active ingredient carriers provided with at least one active ingredient which are provided with an inner layer for controlling the active ingredient release and a covering layer, arranged thereon, that is resistant to gastric juices, and is characterized in that the inner layer is constructed from at least two diffusion layers whose permeability for the diffusing active ingredient decreases from the inside to the outside, and a method for its production are described. Thus (1R,3R,5S)-3-[(Hydroxydiphenylacetyl)oxy]spiro[8-azoniabicyclo[3.2.1]octane-8,1'-pyrrolidinium] chloride-containing pharmaceutical formulations were prepared Pellets contained mg/dose: drug 45.000; neutral pellets 100.000; hypromellose 4.500; Macrogol 6000 0.450; total 154.450. The first diffusion layer was applied onto the above pellets, mg/dose: drug pellet 154.450; Kollicoat SR 30D 9.000; Kollicoat IR 1.800; propyleneglycol 0.900; talc 0.360; total 166.510. The second diffusion layer was applied onto the above coated pellets, mg/dose: drug pellet 166.510; Kollicoat SR 30D 9.000; Kollicoat IR 1.800; propyleneglycol 0.900; talc 0.360; total 177.175. The gastric juice resistant layer was applied onto the above coated pellets, mg/dose: drug pellet (containing 45 mg drug) 177.175, Kollicoat MAE30DP 28.000; talc 12.600; propylene glycol 4.200; Tylopur C30G1 0.720; total 222.695.

IT 286930-02-7
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical preparation for oral administration with controlled active ingredient release in small intestine and methods for its production)
RN 286930-02-7 CAPLUS
CN Propanoic acid, 2-methyl-, 2-[(1R)-3-[bis(1-methylethyl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl ester (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:1454781 CAPLUS
DOCUMENT NUMBER: 148:78876
TITLE: Cyclopentylpyrrolidinone derivatives and their preparation and use in combination therapy for the treatment of urinary frequency, urinary urgency and urinary incontinence
INVENTOR(S): Gottesdiener, Keith M.; Green, Stuart A.; Macintyre, Euan
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 86pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007146224	A2	20071221	WO 2007-US13683	20070607
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: US 2006-812743P P 20060612
GI



I

AB This invention concerns compns. for the treatment of urinary frequency, urinary urgency and urinary incontinence comprising a selected antagonist of the NK-1 receptor or a pharmaceutically acceptable salt thereof and an anti-muscarinic agent or a pharmaceutically acceptable salt thereof. This invention concerns combination therapy for urinary frequency, urinary urgency and urinary incontinence wherein one of the active agents is a selected antagonist of the NK-1 receptor or a pharmaceutically acceptable salt thereof and another is an anti-muscarinic agent or a pharmaceutically acceptable salt thereof. Example compound I was prepared by a multistep procedure (procedure given). All the invention compds. were evaluated for their NK-1 receptor antagonistic activity.

IT 286930-02-7, Fesoterodine
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of cyclopentylpyrrolidinone derivs. as anti-muscarinic agents and NK-1 receptor antagonists in combination therapy of urinary frequency, urinary urgency and urinary incontinence)

RN 286930-02-7 CAPLUS

CN Propanoic acid, 2-methyl-, 2-[(1R)-3-[bis(1-methylethyl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl ester (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L7 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:1425394 CAPLUS
DOCUMENT NUMBER: 148:45893
TITLE: Treatment of excess sebum production

INVENTOR(S): Roach, Alan George; Goldsmith, Paul
PATENT ASSIGNEE(S): Daniolabs Ltd., UK
SOURCE: PCT Int. Appl., 12pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007141530	A2	20071213	WO 2007-GB2098	20070607

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: GB 2006-11240 A 20060607

AB A muscarinic receptor antagonist is useful for the treatment or prevention of a condition associated with excess sebum production or excretion. Muscarinic receptor antagonist oxybutynin dose-dependently reduced sebum production in healthy human volunteers.

IT 286930-02-7, Fesoterodine
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(muscarinic receptor antagonist for treatment of excess sebum production)

RN 286930-02-7 CAPLUS

CN Propanoic acid, 2-methyl-, 2-[(1R)-3-[bis(1-methylethyl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl ester (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L7 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:1420174 CAPLUS
DOCUMENT NUMBER: 148:62011
TITLE: Stabilized pharmaceutical compositions comprising fesoterodine
INVENTOR(S): Arth, Christoph; Mika, Hans-Juergen; Komenda, Michael; Lindner, Hans; Bicane, Fatima; Paulus, Kerstin; Irngartiner, Meike
PATENT ASSIGNEE(S): Schwarz Pharma AG, Germany

SOURCE: PCT Int. Appl., 74pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007141298	A1	20071213	WO 2007-EP55582	20070606
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1864651	A1	20071212	EP 2006-11942	20060609
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
EP 1864656	A1	20071212	EP 2006-11943	20060609
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
EP 1867328	A1	20071219	EP 2006-11941	20060609
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				

PRIORITY APPLN. INFO.:
EP 2006-11941 A 20060609
EP 2006-11942 A 20060609
EP 2006-11943 A 20060609

AB The present application relates to a pharmaceutical composition comprising fesoterodine or a pharmaceutically acceptable salt or solvate thereof and a stabilizer selected from the group consisting of xylitol, sorbitol, polydextrose, isomalt and dextrose. A tablet contained fesoterodine hydrogen fumarate 4.0, xylitol 76.0, lactose monohydrate 43.0, microcryst. cellulose 41.5, hypromellose (e.g. Methocel K100M) 70.0, hypromellose (e.g. Methocel K4M) 70.0, glycerol dibehenate 8.0, talc 7.5, and purified water q.s.

IT 286930-02-7, Fesoterodine 286930-03-8
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(stabilized pharmaceutical compns. comprising fesoterodine)

RN 286930-02-7 CAPLUS

CN Propanoic acid, 2-methyl-, 2-[(1R)-3-[bis(1-methylethyl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl ester (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 286930-03-8 CAPLUS
CN Propanoic acid, 2-methyl-, 2-[(1R)-3-[bis(1-methylethyl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl ester, (2E)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 286930-02-7
CMF C26 H37 N O3

Absolute stereochemistry. Rotation (+).



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:940100 CAPLUS
DOCUMENT NUMBER: 147:269265
TITLE: Combination of an α2-receptor agonist (such as clonidine) and an antimuscarinic agent (such as oxybutynin) for the treatment of sialorrhea
INVENTOR(S): Roach, Alan George; Goldsmith, Paul

PATENT ASSIGNEE(S): Daniolabs Ltd., UK
SOURCE: PCT Int. Appl., 16pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007093824	A1	20070823	WO 2007-GB50057	20070212

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: GB 2006-2855 A 20060213
GB 2006-2857 A 20060213

AB An α2-adrenoreceptor agonist (e.g. clonidine, brimonidine, monoxidine, lofexidine) is useful for the treatment of sialorrhea, administered by the paralingual, sublingual or buccal route. The patient to be treated is also given an antimuscarinic agent (e.g. oxybutynin, glycopyrrolate, ipratropium).

IT 286930-02-7, Fesoterodine
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(α2-receptor agonist-antimuscarinic agent combination for treatment of sialorrhea)

RN 286930-02-7 CAPLUS
CN Propanoic acid, 2-methyl-, 2-[(1R)-3-[bis(1-methylethyl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl ester (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:705973 CAPLUS
DOCUMENT NUMBER: 147:125829
TITLE: Pharmaceutical combination comprising a PED5 inhibitor and a muscarinic antagonist for the treatment of LUTS
INVENTOR(S): Mastrell, Carl Erik Johan; Suesserman, Michael Allen

PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 32pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007072169	A2	20070628	WO 2006-IB3683	20061219
WO 2007072169	A3	20071101		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

JP 2007169278	A	20070705	JP 2006-341662	20061219
PRIORITY APPLN. INFO.:			US 2005-752625P	P 20051220
			US 2006-757720P	P 20060109

GI



I

AB This invention relates to the combined use of a phosphodiesterase 5 (PDE5) inhibitor and a muscarinic antagonist in the treatment of lower urinary tract symptoms (LUTS), such as urgency, frequency, nocturia and urge incontinence. A method of treatment of LUTS comprises simultaneous, sep., or sequential administration of a PED5 inhibitor and a muscarinic antagonist to a patient in need of such treatment. Thus, a muscarinic antagonist, oxybutynin (3.18 mg/kg) produced a small increase in micturition pressure, whereas the PED5 inhibitor, 3-ethyl-5-[5-(4-ethylpiperazin-1-ylsulfonyl)-2-n-propoxyphenyl]-1-(pyridin-2-yl)methyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (I, 0.11 mg/kg and 0.32 mg/kg) produced a small reduction in micturition pressure in guinea pigs. The combination of oxybutynin (3.18 mg/kg) plus I (0.32 mg/kg) produced a greater reduction in micturition pressure than observed with I (0.32 mg/kg) alone. These data appear to imply a synergistic effect of oxybutynin and the higher dose of I tested on micturition pressure. Also, an immediate-release tablet containing fesoterodine (muscarinic antagonist) and 5-[2-ethoxy-5-(4-ethylpiperazine-1-sulfonyl)pyridin-3-yl]-3-ethyl-2-(2-methoxyethyl)-2,6-dihydropyrazolo[4,3-d]pyrimidin-7-one (PED5 inhibitor) were prepared comprising (i) a core containing fesoterodine hydrogen fumarate 2.0 mg, 5-[2-ethoxy-5-(4-ethylpiperazine-1-sulfonyl)pyridin-3-yl]-3-ethyl-

2-(2-methoxyethyl)-2,6-dihydropyrazolo[4,3-d]pyrimidin-7-one besylate 5.0 mg, microcryst. cellulose 53.4 mg, calcium hydrogen phosphate dihydrate 18.0 mg, sodium starch glycollate 6.0 mg, magnesium stearate 0.4 mg, and colloidal silica 0.2 mg, and (ii) a coating containing methylhydroxypropyl cellulose 1.5 mg, microcryst. cellulose 0.3 mg, stearic acid 0.6 mg, and titanium dioxide E 171 0.6 mg.

IT 286930-02-7, Fesoterodine 286930-03-8
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. comprising PED5 inhibitor and muscarinic antagonist for treatment of lower urinary tract disorders)

RN 286930-02-7 CAPLUS
CN Propanoic acid, 2-methyl-, 2-[(1R)-3-[bis(1-methylethyl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl ester (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 286930-03-8 CAPLUS
CN Propanoic acid, 2-methyl-, 2-[(1R)-3-[bis(1-methylethyl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl ester, (2E)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 286930-02-7
CMF C26 H37 N O3

Absolute stereochemistry. Rotation (+).



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



L7 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:630212 CAPLUS
DOCUMENT NUMBER: 145:110309
TITLE: Injectable sustained release microspheric preparation of 3,3-diphenylpropylamine derivatives as muscarinic receptor antagonists
INVENTOR(S): Li, Youxin
PATENT ASSIGNEE(S): Peop. Rep. China
SOURCE: PCT Int. Appl., 36 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Chinese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006066509	A1	20060629	WO 2005-CN2277	20051222
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
CN 1795845	A	20060705	CN 2004-10101721	20041223
PRIORITY APPLN. INFO.:			CN 2004-10101721 A	20041223

OTHER SOURCE(S): MARPAT 145:110309
GI



I

AB The invention relates to injectable sustained release microspheric preparation of 3,3-diphenylpropylamine, its preparing process and application. The said sustained release microspheric preparation consists of 3,3-diphenylpropylamine of formula I as follows, its optical enantiomers or racemates and one or more medicinal biodegradable high-mol. auxiliary material and other medicinal auxiliary material, wherein the definition of R1, R2 R3 R4 and

R5 sees the claims. The injectable sustained release microspheric preparation according to the invention is used for treatment or supplementary treatment of diseases related to the muscarinic receptor and unstable or overactive bladder such as urgency or stress urinary incontinence, urge incontinence, urinary urgency or frequency, etc.

IT 286930-02-7 895137-80-1
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(injectable sustained release microspheric preparation of 3,3-diphenylpropylamine derivs. as muscarinic receptor antagonists)

RN 286930-02-7 CAPLUS
CN Propanoic acid, 2-methyl-, 2-[(1R)-3-[bis(1-methylethyl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl ester (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 895137-80-1 CAPLUS
CN Benzenemethanol, 4-(acetyloxy)-3-[(1R)-3-[bis(1-methylethyl)amino]-1-phenylpropyl]- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:76147 CAPLUS
DOCUMENT NUMBER: 144:156740
TITLE: Combinations of statins with bronchodilators for treatment of respiratory disorders
INVENTOR(S): Lindmark, Bertil; Thoren, Anders Ingemar
PATENT ASSIGNEE(S): AstraZeneca AB, Swed.; AstraZeneca UK Limited
SOURCE: PCT Int. Appl., 18 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006008437	A1	20060126	WO 2005-GB2413	20050620
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2005263883	A1	20060126	AU 2005-263883	20050620
CA 2573393	A1	20060126	CA 2005-2573393	20050620
EP 1773319	A1	20070418	EP 2005-752046	20050620
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
CN 1984653	A	20070620	CN 2005-80023801	20050620
US 2008004247	A1	20080103	US 2007-571869	20070109
MX 200700424	A	20070307	MX 2007-424	20070111
KR 2007031392	A	20070319	KR 2007-700831	20070112
NO 2007000651	A	20070205	NO 2007-651	20070205
IN 2007DN01182	A	20070427	IN 2007-DN1182	20070213
PRIORITY APPLN. INFO.:			GB 2004-15789 A	20040715
			WO 2005-GB2413 W	20050620

AB The invention provides medicaments comprising combinations of bronchodilators, glucocorticosteroids and HMG-CoA reductase inhibitors in the treatment of respiratory disorders such as chronic obstructive pulmonary disease (COPD). For example, a metered dose inhaler contained per dose formoterol fumarate dihydrate 4.5 μg, budesonide 160 μg, rosuvastatin 1 mg, and HFA 227 50 μL. Also, an inhalation/oral combination comprised an aerosol formulation containing per dose formoterol fumarate dihydrate 4.5 μg and budesonide 160 μg, and a tablet formulation containing rosuvastatin 10 mg.

IT 286930-02-7, Fesoterodine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combinations of statins with bronchodilators for treatment of respiratory disorders)

RN 286930-02-7 CAPLUS

CN Propanoic acid, 2-methyl-, 2-[(1R)-3-[bis(1-methylethyl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl ester (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS

L7 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:902168 CAPLUS
DOCUMENT NUMBER: 141:374727
TITLE: Method using quaternary ammonium compounds for the treatment of irritable bowel syndrome
INVENTOR(S): Richards, Ivan Michael; Kolbasa, Karen Patrice
PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, LLC, USA
SOURCE: PCT Int. Appl., 37 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004091597	A2	20041028	WO 2004-IB1218	20040405
WO 2004091597	A3	20050414		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004220224	A1	20041104	US 2004-823944	20040413
PRIORITY APPLN. INFO.:			US 2003-462921P P	20030415
OTHER SOURCE(S):	MARPAT 141:374727			

GI



I

AB The invention discloses a method for treating irritable bowel syndrome by administering quaternary ammonium compds. Compds. of the invention include e.g. I [R1 = (un)substituted C1-6 alkyl, (un)substituted CH2(C1-4 alkenyl), (un)substituted CH2(C1-6 alkynyl); X = anion of pharmaceutically acceptable acid]. Preparation of selected compds., e.g. (3R)-3-(2-hydroxy-5-methylphenyl)-N,N-diisopropyl-N-methyl-3-phenylpropan-1-aminium bromide, is included.

IT 518360-93-5
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(quaternary ammonium compds. for treatment of irritable bowel syndrome)

RN 518360-93-5 CAPLUS
CN Benzenepropanaminium, 5-(hydroxymethyl)-N-methyl-N,N-bis(1-methylethyl)-2-(2-methyl-1-oxopropoxy)-γ-phenyl-, bromide, (γR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Br^-

L7 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:878361 CAPLUS
DOCUMENT NUMBER: 141:370546
TITLE: Highly pure bases of 3,3-diphenyl propylamine monoesters for use in transdermal delivery systems
INVENTOR(S): Breitenbach, Armin; Meese, Claus; Wolff, Hans-Michael; Drews, Roland
PATENT ASSIGNEE(S): Schwarz Pharma Ag, Germany
SOURCE: PCT Int. Appl., 72 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004089872	A1	20041021	WO 2004-EP3567	20040403
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10315917	A1	20041118	DE 2003-10315917	20030408
AU 2004228163	A1	20041021	AU 2004-228163	20040403
AU 2004228163	B2	20070607		
CA 2505848	A1	20041021	CA 2004-2505848	20040403
BR 2004006221	A	20050809	BR 2004-6221	20040403
EP 1613584	A1	20060111	EP 2004-725610	20040403
EP 1613584	B1	20071121		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
CN 1802345	A	20060712	CN 2004-80009224	20040403
JP 2006522758	T	20061005	JP 2006-504989	20040403
ZA 2005002679	A	20060426	ZA 2005-2679	20050331

MX 2005PA03562	A	20050603	MX 2005-PA3562		20050401
US 2006014832	A1	20060119	US 2005-532836		20050426
NO 2005005078	A	20051031	NO 2005-5078		20051031
PRIORITY APPLN. INFO.:			DE 2003-10315917	A	20030408
			WO 2004-EP3567	W	20040403

OTHER SOURCE(S): MARPAT 141:370546

GI



I

AB The invention relates to a compound of general formula (I) wherein A represents deuterium or hydrogen, R represents a group selected from C1-6 alkyl, C3-10 cycloalkyl or Ph, which can be substituted by C1-3 alkoxy, fluorine, chlorine, bromine, iodine, nitro, amino, hydroxyl, oxo, mercapto or deuterium. The C atom marked with a * (star) can be present in an (R) configuration, in an (S)-configuration or a mixture thereof. The invention is characterized in that the above-mentioned compds. are free bases with a degree of purity of more than 97 wt %. The invention also relates to a method for the production of highly pure compds. of general formula (I) and to the use thereof in the production of medicaments. Thus (R)-2-[3-(Diisopropylamino)-1-phenylpropyl]-4-(hydroxymethyl)phenol was reacted with isobutyric acid chloride to form fesoterodine. Fesoterodine was purified via the formation of its fumaric acid salt. 1.5 G of the highly pure fesoterodine was mixed with 8.5 g silicone adhesive Bio-PSA 7-4300 and applied to a foil in order to prepare a transdermal delivery system.

IT 286930-02-7P, Fesoterodine
RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(highly pure bases of 3,3-di-Ph propylamine monoesters for use in transdermal delivery systems)

RN 286930-02-7 CAPLUS

CN Propanoic acid, 2-methyl-, 2-[(1R)-3-[bis(1-methylethyl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl ester (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT 777075-72-6P
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(highly pure bases of 3,3-di-Ph propylamine monoesters for use in transdermal delivery systems)
RN 777075-72-6 CAPLUS
CN Propanoic acid, 2-methyl-, 2-[(1R)-3-[bis(1-methylethyl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl ester, carbonate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 286930-02-7
CMF C26 H37 N O3

Absolute stereochemistry. Rotation (+).



CM 2

CRN 463-79-6
CMF C H2 O3



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:878163 CAPLUS

DOCUMENT NUMBER: 141:360690
TITLE: Combination therapies of asthma, COPD, allergic and infectious rhinitis
INVENTOR(S): Richards, Ivan Michael; Manning, Robert Everett
PATENT ASSIGNEE(S): Pfizer Inc, USA
SOURCE: U.S. Pat. Appl. Publ., 20 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004209916	A1	20041021	US 2004-824315	20040413
CA 2522666	A1	20041028	CA 2004-2522666	20040405
WO 2004091596	A2	20041028	WO 2004-IB1170	20040405
WO 2004091596	A3	20050407		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1620083	A2	20060201	EP 2004-725755	20040405
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
BR 2004009492	A	20060502	BR 2004-9492	20040405
JP 2006523674	T	20061019	JP 2006-506483	20040405
MX 2005PA11225	A	20051214	MX 2005-PA11225	20051018

PRIORITY APPLN. INFO.: US 2003-463975P P 20030418
WO 2004-IB1170 W 20040405

OTHER SOURCE(S): MARPAT 141:360690

AB The invention is directed to methods of treating asthma, COPD, allergic rhinitis, and infectious rhinitis by administering a first pharmaceutical agent including one or more compds. selected from the quaternary ammonium compds. (Markush structures are included) and a second pharmaceutical agent including one or more pharmaceutical agents selected from Adenosine A2a Receptor Agonists, D2-Dopamine Receptor Agonists, Phosphodiesterase Inhibitors (PDE's), corticosteroids, norepinephrine reuptake inhibitors, 4-hydroxy-7-[2-[2-[3-[2-phenylethoxy]-propylsulfonyl]ethylamino]ethyl]-1,3-benzothiazol-2(3H)-one, and pharmaceutically acceptable salts thereof, and non-quaternized antimuscarinic compds.

IT 518360-93-5
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination therapies of asthma, COPD, allergic and infectious rhinitis)

RN 518360-93-5 CAPLUS
CN Benzenepropanaminium, 5-(hydroxymethyl)-N-methyl-N,N-bis(1-methylethyl)-2-(2-methyl-1-oxopropoxy)-γ-phenyl-, bromide, (γR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Br^-

L7 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:872676 CAPLUS
DOCUMENT NUMBER: 141:337790
TITLE: Transdermal administration of (R)-3,3-diphenylpropylamine monoesters
INVENTOR(S): Breitenbach, Armin; Meese, Claus; Wolff, Hans-Michael; Drews, Roland
PATENT ASSIGNEE(S): Schwarz Pharma Ag, Germany
SOURCE: PCT Int. Appl., 68 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004089346	A1	20041021	WO 2004-EP3574	20040403
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10315878	A1	20041104	DE 2003-10315878	20030408
AU 2004228927	A1	20041021	AU 2004-228927	20040403
AU 2004228927	B2	20070517		
CA 2505780	A1	20041021	CA 2004-2505780	20040403
EP 1530461	A1	20050518	EP 2004-725614	20040403
EP 1530461	B1	20071003		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004006212	A	20050816	BR 2004-6212	20040403
CN 1767820	A	20060503	CN 2004-80009176	20040403
JP 2006522759	T	20061005	JP 2006-504992	20040403
NZ 539214	A	20070223	NZ 2004-539214	20040403
AT 374605	T	20071015	AT 2004-725614	20040403
MX 2005PA03561	A	20050617	MX 2005-PA3561	20050401
ZA 2005002681	A	20051013	ZA 2005-2681	20050401

US 2006029673	A1	20060209	US 2005-533683		20050426
NO 2005004644	A	20051010	NO 2005-4644		20051010
PRIORITY APPLN. INFO.:			DE 2003-10315878	A	20030408
			WO 2004-EP3574	W	20040403

OTHER SOURCE(S): MARPAT 141:337790
GI



I

AB The invention relates to a device for transdermally administering a compound of formula (I), wherein A represents hydrogen or deuterium, R represents a group selected among C1-6 alkyl, C3-10 cycloalkyl, or Ph, each of which can be substituted by C1-3 alkoxy, fluoride, chlorine, bromine, iodine, nitro, amino, hydroxy, oxo, mercapto, or deuterium, the C atom marked by * (asterisk) being provided in the R configuration. The invention is characterized in that the compound of general formula (I) is provided in a polymer matrix and is released at a dose of 0.5 to 20 mg per day through human skin. The invention further relates to the use of said compds. of formula (I) for producing transdermal medicaments. Thus a silicone-based transdermal system was prepared by the hot-melt process. 8.5 G of an adhesive mixture composed of BIO-PSA 7-4300 from Dow-Corning and 5 weight/weight% ozokerite or ceresin was heated to 150°C for 20 min until a homogeneous melt was formed. 1.5 G fesoterodine were added to the melt; the mixture was kept for addnl. 5 min at 150°C; followed by application onto a preheated foil. 5 Cm2 samples were used for dissoln. studies.

IT 286930-02-7P, Fesoterodine
RL: PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(transdermal administration of (R)-3,3-diphenylpropylamine monoesters)

RN 286930-02-7 CAPLUS

CN Propanoic acid, 2-methyl-, 2-[(1R)-3-[bis(1-methylethyl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl ester (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:950829 CAPLUS
DOCUMENT NUMBER: 140:13084
TITLE: Combination of selected opioids with other active substances for use in the therapy of urinary incontinence
INVENTOR(S): Christoph, Thomas
PATENT ASSIGNEE(S): Grunenthal G.m.b.H., Germany
SOURCE: PCT Int. Appl., 126 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003099268	A1	20031204	WO 2003-EP5529	20030527
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10224107	A1	20031211	DE 2002-10224107	20020529
AU 2003240717	A1	20031212	AU 2003-240717	20030527
EP 1507520	A1	20050223	EP 2003-730120	20030527
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2005137194	A1	20050623	US 2004-998164	20041129
US 2006168942	A1	20060803	US 2005-545901	20050817
US 7246486	B2	20070724		

PRIORITY APPLN. INFO.: DE 2002-10224107 A 20020529
WO 2003-EP5529 W 20030527

OTHER SOURCE(S): MARPAT 140:13084

AB The invention discloses the use of a combination of opioids (e.g. tramadol) with other active substances for producing a drug for the treatment of urinary urgency or urinary incontinence. The invention also relates to corresponding medicaments and to a method for treating urinary urgency or urinary incontinence.

IT 286930-02-7, Fesoterodine
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)
(opioid combination with other active substances for treatment of urinary incontinence)

RN 286930-02-7 CAPLUS

CN Propanoic acid, 2-methyl-, 2-[(1R)-3-[bis(1-methylethyl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl ester (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 14 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1999:736261 CAPLUS

DOCUMENT NUMBER: 131:336818

TITLE: Preparation of 3,3-diphenylpropylamines as antimuscarinic agents.

INVENTOR(S): Sparf, Bengt; Meese, Claus O.

PATENT ASSIGNEE(S): Schwarz Pharma AG, Germany

SOURCE: Eur. Pat. Appl., 27 pp.
CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 957073	A1	19991117	EP 1998-108608	19980512
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
CA 2328920	A1	19991118	CA 1999-2328920	19990511
WO 9958478	A1	19991118	WO 1999-EP3212	19990511
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9941412	A	19991129	AU 1999-41412	19990511
AU 748057	B2	20020530		
BR 9910406	A	20010109	BR 1999-10406	19990511
EP 1077912	A1	20010228	EP 1999-924929	19990511
EP 1077912	B1	20020703		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
HU 2001000779	A2	20010828	HU 2001-779	19990511
TR 200003319	T2	20011221	TR 2000-3319	19990511

AT 220056	T	20020715	AT 1999-924929		19990511
EP 1254890	A1	20021106	EP 2002-13481		19990511
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL					
NZ 507487	A	20021126	NZ 1999-507487		19990511
PT 1077912	T	20021129	PT 1999-924929		19990511
ES 2181443	T3	20030216	ES 1999-924929		19990511
RU 2199525	C2	20030227	RU 2000-125813		19990511
JP 2003519079	T	20030617	JP 2000-548284		19990511
JP 3929702	B2	20070613			
CN 1690041	A	20051102	CN 2005-10070299		19990511
CZ 296605	B6	20060412	CZ 2000-3774		19990511
PL 195581	B1	20071031	PL 1999-347823		19990511
SK 286052	B6	20080205	SK 2000-1547		19990511
ZA 2000005728	A	20010305	ZA 2000-5728		20001017
NO 2000005669	A	20010111	NO 2000-5669		20001110
MX 2000PA11096	A	20020604	MX 2000-PA11096		20001110
US 6713464	B1	20040330	US 2001-700094		20010102
HK 1046269	A1	20050923	HK 2002-107859		20021030
US 2004186061	A1	20040923	US 2004-766263		20040127
US 7230030	B2	20070612			
US 2006270738	A1	20061130	US 2005-201756		20050810
JP 2007084552	A	20070405	JP 2006-283861		20061018
JP 2007204481	A	20070816	JP 2007-39857		20070220
PRIORITY APPLN. INFO.:			EP 1998-108608	A	19980512
			CN 1999-806038	A3	19990511
			EP 1999-924929	A3	19990511
			JP 2000-548284	A3	19990511
			WO 1999-EP3212	W	19990511
			US 2001-700094	A1	20010102
			US 2004-766263	A1	20040127

OTHER SOURCE(S): MARPAT 131:336818

GI



I

AB Title compds. (I; R = H, Me, Et, Pr, Me2CH, Bu, iso-Bu, pentyl, hexyl, PhCH2, alkyl, CHO, Ac, propionyl, isobutyryl, aminocarbonyl, aminosulfonyl, MeO2C, etc.; R1 = H, Me, Et, Pr, Me2CH, Bu, iso-Bu, pentyl, hexyl, PhCH2, alkyl, phenylalkyl; Z = NR8R9; R8, R9 = hydrocarbyl; NR8R9 = atoms to form a ring; with a proviso), were prepared as antimuscarinic agents (no data). Thus, 4-bromophenol, cinnamoyl chloride, and Et3N were stirred 18 h in CH2Cl2 to give 99.8% 3-phenylacrylic acid 4-bromophenyl ester. This was refluxed 2 h with HOAc/H2SO4 to give 43.8% 6-bromo-4-phenylchroman-2-one. The latter was refluxed with benzyl bromide, K2CO3, and NaI in acetone/MeOH to give 102.1% crude Me 3-(2-benzyloxy-5-bromophenyl)-3-phenylpropionate, which was stirred with LiAlH4 in THF to give 96.3% 3-(2-benzyloxy-5-bromophenyl)-3-phenylpropan-1-ol. This was stirred with tosyl chloride and pyridine in CH2Cl2 for 18 h to give 93.6% tosylate ester, which was refluxed 97 h with diisopropylamine in MeCN to give 77.9% [3-(2-benzyloxy-5-bromophenyl)-3-phenylpropyl]diisopropylamine. The latter was converted in several steps to 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenol, which was acylated to give I.

IT 250214-41-6P 250214-42-7P 250214-43-8P
250214-44-9P 250214-45-0P 250214-46-1P
250214-47-2P 250214-48-3P 250214-49-4P
250214-50-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 3,3-diphenylpropylamines as antimuscarinic agents)

RN 250214-41-6 CAPLUS
CN Benzenemethanol, 4-(acetyloxy)-3-[3-[bis(1-methylethyl)amino]-1-phenylpropyl]- (CA INDEX NAME)



RN 250214-42-7 CAPLUS
CN Benzenemethanol, 3-[3-[bis(1-methylethyl)amino]-1-phenylpropyl]-4-(1-oxopropoxy)- (CA INDEX NAME)



RN 250214-43-8 CAPLUS
CN Butanoic acid, 2-[3-[bis(1-methylethyl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl ester (CA INDEX NAME)



RN 250214-44-9 CAPLUS
CN Propanoic acid, 2-methyl-, 2-[3-[bis(1-methylethyl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl ester (CA INDEX NAME)



RN 250214-45-0 CAPLUS
CN Propanoic acid, 2,2-dimethyl-, 2-[3-[bis(1-methylethyl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl ester (CA INDEX NAME)



RN 250214-46-1 CAPLUS
CN Benzenemethanol, 4-(benzoyloxy)-3-[3-[bis(1-methylethyl)amino]-1-phenylpropyl]- (CA INDEX NAME)



RN 250214-47-2 CAPLUS
CN Propanedioic acid, bis[2-[3-[bis(1-methylethyl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl] ester (9CI) (CA INDEX NAME)



RN 250214-48-3 CAPLUS
CN Butanedioic acid, bis[2-[3-[bis(1-methylethyl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl] ester (9CI) (CA INDEX NAME)



RN 250214-49-4 CAPLUS
CN Pentanedioic acid, bis[2-[3-[bis(1-methylethyl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl] ester (9CI) (CA INDEX NAME)



RN 250214-50-7 CAPLUS
CN Hexanedioic acid, bis[2-[3-[bis(1-methylethyl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl] ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> D L6 IBIB ABS HITSTR 1-3

L6 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:1454781 CAPLUS
DOCUMENT NUMBER: 148:78876
TITLE: Cyclopentylpyrrolidinone derivatives and their preparation and use in combination therapy for the treatment of urinary frequency, urinary urgency and urinary incontinence
INVENTOR(S): Gottesdiener, Keith M.; Green, Stuart A.; Macintyre, Euan
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 86pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007146224	A2	20071221	WO 2007-US13683	20070607

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2006-812743P P 20060612

GI



I

AB This invention concerns compns. for the treatment of urinary frequency, urinary urgency and urinary incontinence comprising a selected antagonist of the NK-1 receptor or a pharmaceutically acceptable salt thereof and an anti-muscarinic agent or a pharmaceutically acceptable salt thereof. This invention concerns combination therapy for urinary frequency, urinary urgency and urinary incontinence wherein one of the active agents is a selected antagonist of the NK-1 receptor or a pharmaceutically acceptable salt thereof and another is an anti-muscarinic agent or a pharmaceutically acceptable salt thereof. Example compound I was prepared by a multistep procedure (procedure given). All the invention compds. were evaluated for their NK-1 receptor antagonistic activity.

IT 286930-02-7, Fesoterodine
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of cyclopentylpyrrolidinone derivs. as anti-muscarinic agents and NK-1 receptor antagonists in combination therapy of urinary frequency, urinary urgency and urinary incontinence)

RN 286930-02-7 CAPLUS

CN Propanoic acid, 2-methyl-, 2-[(1R)-3-[bis(1-methylethyl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl ester (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L6 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:878361 CAPLUS
DOCUMENT NUMBER: 141:370546
TITLE: Highly pure bases of 3,3-diphenyl propylamine monoesters for use in transdermal delivery systems
INVENTOR(S): Breitenbach, Armin; Meese, Claus; Wolff, Hans-Michael; Drews, Roland
PATENT ASSIGNEE(S): Schwarz Pharma Ag, Germany
SOURCE: PCT Int. Appl., 72 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004089872	A1	20041021	WO 2004-EP3567	20040403
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10315917	A1	20041118	DE 2003-10315917	20030408
AU 2004228163	A1	20041021	AU 2004-228163	20040403
AU 2004228163	B2	20070607		
CA 2505848	A1	20041021	CA 2004-2505848	20040403
BR 2004006221	A	20050809	BR 2004-6221	20040403
EP 1613584	A1	20060111	EP 2004-725610	20040403
EP 1613584	B1	20071121		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
CN 1802345	A	20060712	CN 2004-80009224	20040403
JP 2006522758	T	20061005	JP 2006-504989	20040403
ZA 2005002679	A	20060426	ZA 2005-2679	20050331
MX 2005PA03562	A	20050603	MX 2005-PA3562	20050401
US 2006014832	A1	20060119	US 2005-532836	20050426
NO 2005005078	A	20051031	NO 2005-5078	20051031
PRIORITY APPLN. INFO.:			DE 2003-10315917 A	20030408
			WO 2004-EP3567 W	20040403

OTHER SOURCE(S): MARPAT 141:370546
GI



I

AB The invention relates to a compound of general formula (I) wherein A represents deuterium or hydrogen, R represents a group selected from C1-6 alkyl, C3-10 cycloalkyl or Ph, which can be substituted by C1-3 alkoxy, fluorine, chlorine, bromine, iodine, nitro, amino, hydroxyl, oxo, mercapto or deuterium. The C atom marked with a * (star) can be present in an (R) configuration, in an (S)-configuration or a mixture thereof. The invention is characterized in that the above-mentioned compds. are free bases with a degree of purity of more than 97 wt %. The invention also relates to a method for the production of highly pure compds. of general formula (I) and to the use thereof in the production of medicaments. Thus (R)-2-[3-(Diisopropylamino)-1-phenylpropyl]-4-(hydroxymethyl)phenol was reacted with isobutyric acid chloride to form fesoterodine. Fesoterodine was purified via the formation of its fumaric acid salt. 1.5 G of the highly pure fesoterodine was mixed with 8.5 g silicone adhesive Bio-PSA 7-4300 and applied to a foil in order to prepare a transdermal delivery system.

IT 286930-02-7P, Fesoterodine
RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(highly pure bases of 3,3-di-Ph propylamine monoesters for use in transdermal delivery systems)

RN 286930-02-7 CAPLUS

CN Propanoic acid, 2-methyl-, 2-[(1R)-3-[bis(1-methylethyl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl ester (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT 777075-72-6P
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(highly pure bases of 3,3-di-Ph propylamine monoesters for use in transdermal delivery systems)

RN 777075-72-6 CAPLUS

CN Propanoic acid, 2-methyl-, 2-[(1R)-3-[bis(1-methylethyl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl ester, carbonate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 286930-02-7
CMF C26 H37 N O3

Absolute stereochemistry. Rotation (+).



CM 2

CRN 463-79-6
CMF C H2 O3



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:872676 CAPLUS
DOCUMENT NUMBER: 141:337790
TITLE: Transdermal administration of (R)-3,3-diphenylpropylamine monoesters
INVENTOR(S): Breitenbach, Armin; Meese, Claus; Wolff, Hans-Michael; Drews, Roland
PATENT ASSIGNEE(S): Schwarz Pharma Ag, Germany
SOURCE: PCT Int. Appl., 68 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004089346	A1	20041021	WO 2004-EP3574	20040403
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,				

LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
TD, TG

DE 10315878	A1	20041104	DE 2003-10315878		20030408
AU 2004228927	A1	20041021	AU 2004-228927		20040403
AU 2004228927	B2	20070517			
CA 2505780	A1	20041021	CA 2004-2505780		20040403
EP 1530461	A1	20050518	EP 2004-725614		20040403
EP 1530461	B1	20071003			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR					
BR 2004006212	A	20050816	BR 2004-6212		20040403
CN 1767820	A	20060503	CN 2004-80009176		20040403
JP 2006522759	T	20061005	JP 2006-504992		20040403
NZ 539214	A	20070223	NZ 2004-539214		20040403
AT 374605	T	20071015	AT 2004-725614		20040403
MX 2005PA03561	A	20050617	MX 2005-PA3561		20050401
ZA 2005002681	A	20051013	ZA 2005-2681		20050401
US 2006029673	A1	20060209	US 2005-533683		20050426
NO 2005004644	A	20051010	NO 2005-4644		20051010
PRIORITY APPLN. INFO.:			DE 2003-10315878	A	20030408
			WO 2004-EP3574	W	20040403

OTHER SOURCE(S): MARPAT 141:337790
GI



I

AB The invention relates to a device for transdermally administering a compound of formula (I), wherein A represents hydrogen or deuterium, R represents a group selected among C1-6 alkyl, C3-10 cycloalkyl, or Ph, each of which can be substituted by C1-3 alkoxy, fluoride, chlorine, bromine, iodine, nitro, amino, hydroxy, oxo, mercapto, or deuterium, the C atom marked by * (asterisk) being provided in the R configuration. The invention is characterized in that the compound of general formula (I) is provided in a polymer matrix and is released at a dose of 0.5 to 20 mg per day through human skin. The invention further relates to the use of said compds. of formula (I) for producing transdermal medicaments. Thus a silicone-based transdermal system was prepared by the hot-melt process. 8.5 G of an adhesive mixture composed of BIO-PSA 7-4300 from Dow-Corning and 5 weight/weight% ozokerite or ceresin was heated to 150°C for 20 min until a homogeneous melt was formed. 1.5 G fesoterodine were added to the melt; the mixture was kept for addnl. 5 min at 150°C; followed by application onto a preheated foil. 5 Cm2 samples were used for dissoln. studies.

IT 286930-02-7P, Fesoterodine

RL: PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(transdermal administration of (R)-3,3-diphenylpropylamine monoesters)

RN 286930-02-7 CAPLUS

CN Propanoic acid, 2-methyl-, 2-[(1R)-3-[bis(1-methylethyl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl ester (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> D L5 IBIB ABS HITSTR 1

L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:872676 CAPLUS

DOCUMENT NUMBER: 141:337790

TITLE: Transdermal administration of (R)-3,3-diphenylpropylamine monoesters

INVENTOR(S): Breitenbach, Armin; Meese, Claus; Wolff, Hans-Michael; Drews, Roland

PATENT ASSIGNEE(S): Schwarz Pharma Ag, Germany

SOURCE: PCT Int. Appl., 68 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004089346	A1	20041021	WO 2004-EP3574	20040403
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10315878	A1	20041104	DE 2003-10315878	20030408
AU 2004228927	A1	20041021	AU 2004-228927	20040403
AU 2004228927	B2	20070517		
CA 2505780	A1	20041021	CA 2004-2505780	20040403

EP 1530461	A1	20050518	EP 2004-725614		20040403
EP 1530461	B1	20071003			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR					
BR 2004006212	A	20050816	BR 2004-6212		20040403
CN 1767820	A	20060503	CN 2004-80009176		20040403
JP 2006522759	T	20061005	JP 2006-504992		20040403
NZ 539214	A	20070223	NZ 2004-539214		20040403
AT 374605	T	20071015	AT 2004-725614		20040403
MX 2005PA03561	A	20050617	MX 2005-PA3561		20050401
ZA 2005002681	A	20051013	ZA 2005-2681		20050401
US 2006029673	A1	20060209	US 2005-533683		20050426
NO 2005004644	A	20051010	NO 2005-4644		20051010
PRIORITY APPLN. INFO.:			DE 2003-10315878	A	20030408
			WO 2004-EP3574	W	20040403

OTHER SOURCE(S): MARPAT 141:337790

GI



I

AB The invention relates to a device for transdermally administering a compound of formula (I), wherein A represents hydrogen or deuterium, R represents a group selected among C1-6 alkyl, C3-10 cycloalkyl, or Ph, each of which can be substituted by C1-3 alkoxy, fluoride, chlorine, bromine, iodine, nitro, amino, hydroxy, oxo, mercapto, or deuterium, the C atom marked by * (asterisk) being provided in the R configuration. The invention is characterized in that the compound of general formula (I) is provided in a polymer matrix and is released at a dose of 0.5 to 20 mg per day through human skin. The invention further relates to the use of said compds. of formula (I) for producing transdermal medicaments. Thus a silicone-based transdermal system was prepared by the hot-melt process. 8.5 G of an adhesive mixture composed of BIO-PSA 7-4300 from Dow-Corning and 5 weight/weight% ozokerite or ceresin was heated to 150°C for 20 min until a homogeneous melt was formed. 1.5 G fesoterodine were added to the melt; the mixture was kept for addnl. 5 min at 150°C; followed by application onto a preheated foil. 5 Cm2 samples were used for dissoln. studies.

IT 286930-02-7P, Fesoterodine
RL: PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(transdermal administration of (R)-3,3-diphenylpropylamine monoesters)

RN 286930-02-7 CAPLUS

CN Propanoic acid, 2-methyl-, 2-[(1R)-3-[bis(1-methylethyl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl ester (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	114.26	293.29

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-14.40	-14.40

STN INTERNATIONAL LOGOFF AT 12:45:10 ON 25 FEB 2008

#2 10/533,683

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1621con

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	OCT 02	CA/CAplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS 3	OCT 19	BEILSTEIN updated with new compounds
NEWS 4	NOV 15	Derwent Indian patent publication number format enhanced
NEWS 5	NOV 19	WPIX enhanced with XML display format
NEWS 6	NOV 30	ICSD reloaded with enhancements
NEWS 7	DEC 04	LINPADOCDB now available on STN
NEWS 8	DEC 14	BEILSTEIN pricing structure to change
NEWS 9	DEC 17	USPATOLD added to additional database clusters
NEWS 10	DEC 17	IMSDRUGCONF removed from database clusters and STN
NEWS 11	DEC 17	DGENE now includes more than 10 million sequences
NEWS 12	DEC 17	TOXCENTER enhanced with 2008 MeSH vocabulary in MEDLINE segment
NEWS 13	DEC 17	MEDLINE and LMEDLINE updated with 2008 MeSH vocabulary
NEWS 14	DEC 17	CA/CAplus enhanced with new custom IPC display formats
NEWS 15	DEC 17	STN Viewer enhanced with full-text patent content from USPATOLD
NEWS 16	JAN 02	STN pricing information for 2008 now available
NEWS 17	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS 18	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS 19	JAN 28	MARPAT searching enhanced
NEWS 20	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS 21	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS 22	JAN 28	MEDLINE and LMEDLINE reloaded with enhancements
NEWS 23	FEB 08	STN Express, Version 8.3, now available
NEWS 24	FEB 20	PCI now available as a replacement to DPCI
NEWS 25	FEB 25	IFIREF reloaded with enhancements
NEWS 26	FEB 25	IMSPRODUCT reloaded with enhancements

NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

```
* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 15:44:55 ON 25 FEB 2008

=> FILE REG
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.42       0.42

FILE 'REGISTRY' ENTERED AT 15:45:58 ON 25 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   24 FEB 2008  HIGHEST RN 1005323-41-0
DICTIONARY FILE UPDATES:  24 FEB 2008  HIGHEST RN 1005323-41-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\LC-53.str
```





chain nodes :
13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33
34 35 36
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12
chain bonds :
1-19 2-31 3-17 4-29 5-30 6-13 7-35 8-34 9-33 10-32 11-19 12-36 13-14
14-15 14-16 17-18 19-20 20-21 21-22 22-23 22-26 23-24 23-25 26-27 26-28
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12
exact/norm bonds :
6-13 13-14 14-15 14-16 17-18 22-23 22-26
exact bonds :
1-19 2-31 3-17 4-29 5-30 7-35 8-34 9-33 10-32 11-19 12-36 19-20 20-21
21-22 23-24 23-25 26-27 26-28
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12

G1:Cb,Cy,Ak

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS
19:CLASS 20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS
27:CLASS 28:CLASS 29:CLASS 30:CLASS 31:CLASS 32:CLASS 33:CLASS 34:CLASS
35:CLASS 36:CLASS

```
L1      STRUCTURE UPLOADED

=> S L1 FULL
FULL SEARCH INITIATED 15:47:34 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -       84 TO ITERATE

100.0% PROCESSED       84 ITERATIONS                                19 ANSWERS
SEARCH TIME: 00.00.01

L2           19 SEA SSS FUL L1

=> FILE CAPLUS
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                     179.28     179.70

FILE 'CAPLUS' ENTERED AT 15:47:47 ON 25 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 25 Feb 2008  VOL 148 ISS 9
FILE LAST UPDATED: 24 Feb 2008  (20080224/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> S L2
L3           31 L2

=> S L3 AND SKIN
        274112 SKIN
L4            1 L3 AND SKIN

=> D L4 IBIB ABS HITSTR 1

L4   ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:         2004:872676  CAPLUS
DOCUMENT NUMBER:          141:337790
TITLE:                    Transdermal administration of (R)-3,3-
                          diphenylpropylamine monoesters
INVENTOR(S):              Breitenbach, Armin; Meese, Claus; Wolff, Hans-Michael;
                          Drews, Roland
PATENT ASSIGNEE(S):       Schwarz Pharma Ag, Germany
SOURCE:                   PCT Int. Appl., 68 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 German
FAMILY ACC. NUM. COUNT:   1
```

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004089346	A1	20041021	WO 2004-EP3574	20040403
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10315878	A1	20041104	DE 2003-10315878	20030408
AU 2004228927	A1	20041021	AU 2004-228927	20040403
AU 2004228927	B2	20070517		
CA 2505780	A1	20041021	CA 2004-2505780	20040403
EP 1530461	A1	20050518	EP 2004-725614	20040403
EP 1530461	B1	20071003		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004006212	A	20050816	BR 2004-6212	20040403
CN 1767820	A	20060503	CN 2004-80009176	20040403
JP 2006522759	T	20061005	JP 2006-504992	20040403
NZ 539214	A	20070223	NZ 2004-539214	20040403
AT 374605	T	20071015	AT 2004-725614	20040403
MX 2005PA03561	A	20050617	MX 2005-PA3561	20050401
ZA 2005002681	A	20051013	ZA 2005-2681	20050401
US 2006029673	A1	20060209	US 2005-533683	20050426
NO 2005004644	A	20051010	NO 2005-4644	20051010
PRIORITY APPLN. INFO.:			DE 2003-10315878 A	20030408
			WO 2004-EP3574 W	20040403

OTHER SOURCE(S): MARPAT 141:337790

GI



I

AB The invention relates to a device for transdermally administering a compound of formula (I), wherein A represents hydrogen or deuterium, R represents a group selected among C1-6 alkyl, C3-10 cycloalkyl, or Ph, each of which can be substituted by C1-3 alkoxy, fluoride, chlorine, bromine, iodine, nitro, amino, hydroxy, oxo, mercapto, or deuterium, the C atom marked by * (asterisk) being provided in the R configuration. The invention is characterized in that the compound of general formula (I) is provided in a polymer matrix and is released at a dose of 0.5 to 20 mg per day through

human skin. The invention further relates to the use of said compds. of formula (I) for producing transdermal medicaments. Thus a silicone-based transdermal system was prepared by the hot-melt process. 8.5 G of an adhesive mixture composed of BIO-PSA 7-4300 from Dow-Corning and 5 weight/weight% ozokerite or ceresin was heated to 150°C for 20 min until a homogeneous melt was formed. 1.5 G fesoterodine were added to the melt; the mixture was kept for addnl. 5 min at 150°C; followed by application onto a preheated foil. 5 Cm2 samples were used for dissoln. studies.

IT 286930-02-7P, Fesoterodine
RL: PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(transdermal administration of (R)-3,3-diphenylpropylamine monoesters)

RN 286930-02-7 CAPLUS

CN Propanoic acid, 2-methyl-, 2-[(1R)-3-[bis(1-methylethyl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl ester (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	8.53	188.23

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.80	-0.80

STN INTERNATIONAL LOGOFF AT 15:49:09 ON 25 FEB 2008